Unfortunately, in a phase II trial with 39 SCLC patients using the dual BCL-2 and BCL-XL inhibitor, navitoclax (ABT-263), only 1 patient achieved a partial response and 8 patients had stable disease [8]. The gene discussed is BCL2; the disease is small cell lung carcinoma.